COVID-19 Study of Safety and Tolerability of Alvelestat (COSTA)

• ClinicalTrials.gov Identifier: NCT04539795
• Recruitment Status: Completed
• First Posted: September 7, 2020
• Results First Posted: January 19, 2023
• Last Update Posted: January 19, 2023
• Sponsor: University of Alabama at Birmingham
• Collaborator: Mereo BioPharma
• Information provided by (Responsible Party): James Michael Wells, University of Alabama at Birmingham

Study Description

Brief Summary:

The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK), and explore the mechanistic and clinical effect of alvelestat (an oral neutrophil elastase inhibitor) orally twice per day for 10 days added to standard of care in adult patients (≥18 years) with COVID-19 respiratory disease.

Condition or disease	Intervention/treatment	Phase
Covid19	Drug: Alvelestat; Drug: Placebo	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 15 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase Ib/II, Single Center, Placebo-Controlled, Randomized, Blinded Study in Adult Patients (> 18 Years) With COVID-19 Respiratory Disease, to Evaluate, Safety, Tolerability and Mechanistic Effect of Alvelestat on Top of Standard of Care (COSTA)
• Actual Study Start Date: January 25, 2021
• Actual Primary Completion Date: October 29, 2021
• Actual Study Completion Date: October 29, 2021

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo oral tablet; placebo	Drug: Placebo; oral tablet
Active Comparator: Alvelestat oral tablet - dose 1; MPH966	Drug: Alvelestat; oral tablet; Other Name: MPH966
Active Comparator: Alvelestat oral tablet - dose 2; MPH966	Drug: Alvelestat; oral tablet; Other Name: MPH966
Active Comparator: Alvelestat oral tablet - dose 3; MPH966	Drug: Alvelestat; oral tablet; Other Name: MPH966

Outcome Measures

Primary Outcome Measures :

1. Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event [ Time Frame: to day 60 ]
   Safety Outcome Assessment

Secondary Outcome Measures :

1. Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of NETosis [ Time Frame: Randomization through Day 10 or hospital discharge, whichever was shorter. ]
   Change in blood markers of NETosis
2. Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of Inflammation [ Time Frame: Randomization through Day 10 or hospital discharge, whichever was shorter. ]
   Change in blood markers of inflammation
3. Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of D-dimer [ Time Frame: Randomization through Day 10 or hospital discharge, whichever was shorter. ]
   Change in blood markers of d-dimer
4. Effect of Alvelestat on Blood Pharmacodynamic Biomarkers of Desmosine [ Time Frame: Randomization through Day 10 or hospital discharge, whichever was shorter. ]
   Change in blood markers of desmosine
5. Mortality Rate [ Time Frame: to Day 90 ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or Female
• Age ≥18 years
• Proven SARS-Cov-2 infection (confirmed by PCR from a nasopharyngeal or lower respiratory tract sample)
• A score of Grade 3 to 5 on the WHO 9-point Ordinal Scale
• Male participants must agree to use a highly effective contraception during the treatment period and for at least 4 days after the last dose of study treatment and refrain from donating sperm during this period.
• Female participants are eligible to participate if not pregnant; not breastfeeding; and at least one of the following conditions is met:

Not a woman of childbearing potential OR A woman of childbearing potential who agrees to follow the contraceptive guidance during the treatment phase and for at least 4 days after the last dose of study medication - Capable of giving signed informed consent which includes a commitment to comply with the requirements and restrictions listed in the informed consent form (ICF) and within this protocol.

Exclusion Criteria:

• Patients who have previously had a score of 6 or 7 on the WHO 9-point Ordinal Scale
• Patients who require support with invasive mechanical ventilation at the time of inclusion, or expected to be required within 24 hours of randomization
• Alanine aminotransferase (ALT) OR aspartate aminotransferase (AST) >2 × the upper limit of normal (ULN) OR Total Bilirubin > ULN. In patients with a documented history of Gilbert's Syndrome AND baseline total bilirubin elevation consistent with an exacerbation of Gilbert's Syndrome (i.e. no other cause of total bilirubin elevation), subjects may enroll if total bilirubin is < 5x ULN.
• Diagnosis of liver cirrhosis, esophageal varices, ascites or hepatic encephalopathy
• Chronic liver diseases such as autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, haemochromatosis
• Significant renal disease or infection (as determined by the Investigator) including stage 4 chronic kidney disease or estimated glomerular filtration rate <60mL/min
• Absolute neutrophil count ≤ 1000/µL at screening
• Myocardial infarction, transient ischemic attack or stroke within 3 months prior to the first dose
• Current unstable angina or congestive heart failure (New York Heart Association III/IV)
• Screening 12-lead EKG with a measurable QTc interval according to Fridericia correction (QTcF) >450 ms
• Anticipated transfer to another hospital that is not the study center within 24 hours
• Allergy to study medication or excipients
• Inability to swallow tablets
• Other documented comorbidities or laboratory abnormalities that in the opinion of the Investigator could affect the outcome of the study assessments, participant safety, or ability of the participant to comply with the requirements of the protocol
• Any patient whose interests are not best served by study participation, as determined by the Investigator

Excluded Prior/Concomitant Therapy

• Requirement for medications mainly metabolized by CYP2C9 and with narrow therapeutic index (eg, warfarin, phenytoin) is prohibited unless therapeutic monitoring available for duration of alvelestat dosing
• Medicines that are potent CYP3A4 inhibitors including (but are not limited to) clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, ritonavir, verapamil and potent inducers including but not limited to phenobarbital, phenytoin and rifampicin, will be exclusionary
• Requirement for medications substantially reliant on OATP1B1 for metabolism where discontinuation during study drug administration is not possible or where fluctuations in levels are considered clinically important (as per investigator judgement) and cannot be clinically monitored (e.g., statins, valsartan, olmesartan, enalapril, repaglinide)

Excluded Prior/Concurrent Clinical Study Experience

- Participation in any clinical investigation using investigational treatments within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the initial dosing (or longer if required by local regulations) is prohibited. Use of remdesivir (Veklury) under the conditions of the authorization for emergency use in the US, and per manufacturer's instructions, is permitted.

Contacts and Locations

Locations

United States, Alabama

UAB Lung Health Center

Birmingham, Alabama, United States, 35294

Sponsors and Collaborators

University of Alabama at Birmingham

Mereo BioPharma

Investigators

• Principal Investigator: James M Wells, MD; The University of Alabama at Birmingham

  Study Documents (Full-Text)

Documents provided by James Michael Wells, University of Alabama at Birmingham:

Study Protocol  [PDF] April 20, 2021

Statistical Analysis Plan  [PDF] December 13, 2021

More Information

• Responsible Party: James Michael Wells, Associate Professor, University of Alabama at Birmingham
• ClinicalTrials.gov Identifier: NCT04539795
• Other Study ID Numbers: IRB-300005845
• First Posted: September 7, 2020
• Results First Posted: January 19, 2023
• Last Update Posted: January 19, 2023
• Last Verified: December 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

COVID-19; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases